Current and future biomarkers in colorectal cancer.

about

Current and future biomarkers in colorectal cancer.

Item

http://www.wikidata.org/entity/Q43492228

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Current and future biomarkers in colorectal cancer.

@en

Current and future biomarkers in colorectal cancer.

@nl

type

Item

label

Current and future biomarkers in colorectal cancer.

@en

Current and future biomarkers in colorectal cancer.

@nl

prefLabel

Current and future biomarkers in colorectal cancer.

@en

Current and future biomarkers in colorectal cancer.

@nl

P1476

Current and future biomarkers in colorectal cancer.

@en

P2093

Alexandra Papadaki

http://www.w3.org/2001/XMLSchema#string

Dimitrios K Christodoulou

http://www.w3.org/2001/XMLSchema#string

George Pentheroudakis

http://www.w3.org/2001/XMLSchema#string

George Zarkavelis

http://www.w3.org/2001/XMLSchema#string

Konstantinos H Katsanos

http://www.w3.org/2001/XMLSchema#string

P2860

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas

Comprehensive molecular characterization of human colon and rectal cancer

CpG island methylator phenotype in colorectal cancer

Diagnostics and Epidemiology of Colorectal Cancer

Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

P304

613-621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.20524/AOG.2017.0191

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stergios Boussios

P577

2017-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29118555

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

biomarker

P932

5670280

http://www.w3.org/2001/XMLSchema#string